Understanding monoclonal antibodies
Elsewhere in this issue, we review new treatments for neovascular age-related macular degeneration,1 of which, 
bevacizumab and ranibizumab are monoclonal antibodies. These are two of a growing number of monoclonal antibodies currently available for therapeutic use in the UK. We have reviewed some of the others before: bevacizumab and cetuximab for colorectal cancer;2 infliximab for rheumatoid arthritis;3 omalizumab for severe asthma;4 and trastuzumab for breast cancer.5 The expanding range of these products and their clinical applications can make it difficult to keep abreast of developments in this field. With this in mind, we describe the key principles underlying the production, use and naming of monoclonal antibodies.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
-
(2009). So, what exactly is a cytokine?. DTB
47: 89-91
[Abstract] [Full Text] -
(2008). {blacktriangledown}Natalizumab for multiple sclerosis?. DTB
46: 69-72
[Abstract] [Full Text]
- Full Text
- Full Text (PDF)
- Submit a response
- Alert me when this article is cited
- Alert me when eLetters are posted
- Alert me if a correction is posted
Services
- Email this link to a friend
- Similar articles in this journal
- Similar articles in PubMed
- Add article to my folders
- Download to citation manager
- Request Permissions
Citing Articles
Google Scholar
PubMed
Topic Collections
-
Respiratory system
-
Malignant disease and immunosuppression
-
Haematology (drugs and medicines)
-
Musculoskeletal and joint disorders
-
Eye
Bookmark with
Register for email alerts
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
Coming soon!
The DTB archive back to 1962, volume 1, issue 1 will soon be available.
